Upon joining the study, you will be required to provide a signed informed consent form. This confirms your understanding and agreement to participate in the trial.

You must be at least 18 years old and have been diagnosed with hidradenitis suppurativa for at least six months. This condition involves painful lumps under the skin.

A baseline assessment will be conducted to evaluate the severity of your condition. This includes counting the number of abscesses and inflammatory nodules, which are types of skin lesions.

The assessment will also determine if the lesions affect at least two different areas of your body.

You will be randomly assigned to receive either the study medication remibrutinib or a placebo. A placebo is a substance with no active medication, used to compare the effects of the actual drug.

The medication is taken orally in the form of a film-coated tablet. The exact dosage and frequency will be provided by the study team.

The treatment period lasts for 68 weeks, during which you will take the medication as instructed.

Throughout the study, regular check-ups will be scheduled to monitor your condition and any changes in your symptoms.

These check-ups will include assessments similar to the baseline assessment to track progress and any side effects.

The primary goal is to achieve a HiSCR50 at week 16, which means at least a 50% reduction in the number of abscesses and nodules without an increase in other symptoms.

Secondary goals include further reductions in symptoms and monitoring any adverse effects during the study.

At the end of the study period, a final assessment will be conducted to evaluate the overall effectiveness and safety of the treatment.

You will be informed of the results and any further steps if necessary.